teduglutide (Gattex)
Peptide
Also known as ALX-0600
Evidence outlook
Approved: Short Bowel Syndrome
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Treatment of short bowel syndrome
- Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery. Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome. Patients should be stable following a period of intestinal adaptation after surgery.
Development in Crohn's Disease stopped (2009) as a strategic decision by the sponsor. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
STEPS NCT00798967 · Short Bowel Syndrome The trial was randomized, quadruple-blind, and placebo-controlled, with 43 participants per group, and its clinical primary endpoint was met (p=0.002). However, the available record does not report the power or sample-size calculation needed to verify that the study was adequately powered, so the evidence is graded moderate rather than strong. Registry: NCT00798967 | 3 | Responder (Weeks 20 and 24) 2011-01-25 | Responder (Weeks 20 and 24): Teduglutide 27 subjects | Placebo 13 subjects | Partial signal | link ↗ |
View 5 more trials
NCT00930644 NCT00930644 · Short Bowel Syndrome This was an open-label, single-group extension of the completed CL0600-020 trial, enrolling 88 participants and continuing teduglutide without a concurrent placebo or active-control arm. The primary clinical endpoint was reported descriptively, with no formal significance test establishing that one treatment group was superior to another, so the findings provide limited evidence despite the clearly identified extension population. Registry: NCT00930644 | 3 | Percent Change in PN/IV Volume by Visit (24 months); Absolute Change in PN/IV Volume by Visit (24 months) 2013-01-24 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT00081458 NCT00081458 · Short Bowel Syndrome The study was randomized, triple-blind, placebo-controlled, and included 84 participants, with a clinical primary endpoint measuring sustained reduction in parenteral nutrition requirements; the primary comparison was statistically significant (p=0.007). However, the available record does not report a sample-size or power calculation, so the study’s power cannot be confirmed. Registry: NCT00081458 | 3 | A Graded Response Score in Parenteral Nutrition (PN) Reduction (6 months) 2007-07-06 | A Graded Response Score in Parenteral Nutrition (PN) Reduction (6 months): Placebo — 0 (No Response): 15 participants; 1: 0 participants; 2: 1 participants; 4: 0 participants; 5 (No longer need PN): 0 participants | Teduglutide 0.05 mg/kg/d — 0 (No Response): 19 participants; 1: 6 participants; 2: 6 participants; 4: 2 participants; 5 (No longer need PN): 2 participants | Teduglutide 0.1 mg/kg/d — 0 (No Response): 24 participants; 1: 2 participants; 2: 4 participants; 4: 2 participants; 5 (No longer need PN): 0 participants | Partial signal | link ↗ |
NCT00172185 NCT00172185 · Short Bowel Syndrome This study continued participants from the completed randomized trial CL0600-004 (NCT00081458); everyone received teduglutide, so there is no placebo comparison. Results are reported as counts per dose group without any statistical test, which gives supportive long-term information rather than a controlled test of benefit. Registry: NCT00172185 | 3 | Number of Subjects Achieving a 20% Reduction at Week 28 (28 weeks) 2008-01-24 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT02682381 NCT02682381 · Short Bowel Syndrome Children were randomized and blinded between two teduglutide doses, but the only comparison group was a small observational standard-of-care cohort of 9 children who were not randomized. Response counts are posted (18 of 26 on 0.05 mg/kg/day vs 1 of 9 on standard care) without any statistical analysis, so the benefit over standard care was not formally tested. Registry: NCT02682381 | 3 | Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 (Baseline through Week 24) 2017-08-18 | Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 (Baseline through Week 24): 0.025 mg/kg/Day Teduglutide — Participant Diary: 13 Participants; Investigator Prescribed: 13 Participants | 0.05 mg/kg/Day Teduglutide — Participant Diary: 18 Participants; Investigator Prescribed: 18 Participants | Standard of Care — Participant Diary: 1 Participants; Investigator Prescribed: 2 Participants | Partial signal | link ↗ |
NCT02954458 NCT02954458 · Short Bowel Syndrome Registry: NCT02954458 | 3 | Number of Participants With Treatment-emergent Adverse Events (TEAEs) (From start of study drug administration up to follow-up (up to 46 months)); Change From Baseline in Average Total Urine Output at End of Treatment (EOT) of Last Cycle During Teduglutide Treatment (Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)); Change From Baseline in Average Total Urine Output at Last Visit During Non-Teduglutide Treatment (NT) (Baseline, Last visit in NT (up to Month 39)); Change From Baseline in Average Number of Stools Per Day at EOT of Last Cycle During Teduglutide Treatment (Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)); Change From Baseline in Average Number of Stools Per Day at Last Visit During Non-Teduglutide Treatment (NT) (Baseline, Last visit in NT (up to Month 39)); Change From Baseline in Average Total Daily Stool/Mixed Stool Diaper Weight at EOT of Last Cycle During Teduglutide Treatment (Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)); Change From Baseline in Average Total Daily Stool/Mixed Stool Diaper Weight at Last Visit During Non-Teduglutide Treatment (NT) (Baseline, Last visit in NT (up to Month 39)); Change From Baseline in Average Total Ostomy Output at EOT of Last Cycle During Teduglutide Treatment (Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)); Change From Baseline in Average Total Ostomy Output at Last Visit During Non-Teduglutide Treatment (NT) (Baseline, Last visit in NT (up to Month 39)); Change From Baseline in Average Bristol Stool Form Score at EOT of Last Cycle During Teduglutide Treatment (Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)); Change From Baseline in Average Bristol Stool Form Score at Last Visit During Non-Teduglutide Treatment (NT) (Baseline, Last visit in NT (up to Month 39)); Number of Participants With Positive Specific Antibodies at End of Study (EOS) (At EOS (up to 46 months)); Change From Baseline in Body Weight Z-score at EOT of Last Cycle During Teduglutide Treatment (Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)); Change From Baseline in Body Weight Z-score at Last Visit During Non-Teduglutide Treatment (NT) (Baseline, Last visit in NT (up to Month 39)); Change From Baseline in Height Z-score at EOT of Last Cycle During Teduglutide Treatment (Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)); Change From Baseline in Height Z-score at Last Visit During Non-Teduglutide Treatment (Baseline, Last visit in NT (up to Month 39)); Change From Baseline in Head Circumference Z-score at EOT of Last Cycle During Teduglutide Treatment (Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)); Change From Baseline in Head Circumference Z-score at Last Visit During Non-Teduglutide Treatment (NT) (Baseline, Last visit in NT (up to Month 39)); Change From Baseline in Body Mass Index (BMI) Z-score at EOT of Last Cycle During Teduglutide Treatment (Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)); Change From Baseline in Body Mass Index (BMI) Z-score at Last Visit During Non-Teduglutide Treatment (NT) (Baseline, Last visit in NT (up to Month 39)) 2020-11-05 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other GLP-2 receptor drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Short Bowel Syndrome: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Teduglutide (Gattex): this drug | Approved | Peptide | GLP-2 receptor | Partial signal | NCT02682381: Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 (Baseline through Week 24): 0.025 mg/kg/Day Teduglutide — Participant Diary: 13 Participants; Investigator Prescribed: 13 Participants | 0.05 mg/kg/Day Teduglutide — Participant Diary: 18 Participants; Investigator Prescribed: 18 Participants | Standard of Care — Participant Diary: 1 Participants; Investigator Prescribed: 2 Participants NCT00798967: Responder (Weeks 20 and 24): Teduglutide 27 subjects | Placebo 13 subjects | |
| Apraglutide | Phase 3 | Peptide | GLP-2 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Crofelemer (Mytesi) | Phase 2 | Small molecule | Chloride channel (intestinal epithelium) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow teduglutide (Gattex) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.